Home
Search

Letters, Testimony & Comments

BIO submits letters, testimony, and comments to government and regulatory bodies throughout the United States and around the world.

Featured Letters, Testimony, & Comments
John F. Crowley's Annual Letter to BIO Membership
Dear Colleagues,  I am just past the two-year mark as BIO’s President & CEO, which arrives as we find ourselves at a defining moment for the future of biotechnology. For fifty years, our industry has delivered one of the great…
Learn more
BIO Comments on Global Benchmark for Efficient…
Learn more
BIO Comments on Guarding U.S. Medicare Against…
Learn more
All Letters, Testimony & Comments
  • Show All
Search
John F. Crowley's Annual Letter to BIO Membership
April 8, 2026
Dear Colleagues,  I am just past the two-year mark as BIO’s President & CEO, which arrives as we find ourselves at a defining moment for the future of biotechnology. For fifty years, our industry has delivered one of the great…
BIO Comments on Global Benchmark for Efficient Drug Pricing (GLOBE) Model (CMS-5545-P)
February 23, 2026
BIO Comments on Guarding U.S. Medicare Against Rising Drug Costs (GUARD) Model (CMS-5546-P)
February 23, 2026
Testimony of John F. Crowley President and CEO, BIO House Committee on Energy and Commerce Subcommittee on Health Hearing on “Lowering Health Care Costs for All Americans: An Examination of the Prescription Drug Supply Chain"
February 11, 2026
Chairman Griffith, Chairman Guthrie, Ranking Member DeGette, Ranking Member Pallone, and distinguished members of the subcommittee, thank you for the opportunity to appear before you today on behalf of the Biotechnology Innovation Organization (BIO)…
Letter From BIO President & CEO John F. Crowley to Senate and House Leadership on GLOBE GUARD
February 9, 2026
Dear Mr. Thune, Mr. Schumer, Mr. Johnson, and Mr. Jeffries:As President and CEO of the Biotechnology Innovation Organization (BIO), as a father and entrepreneur whose family is here today because of biotech innovation, and on behalf of the more than…
CSBA Letter to Congressional Leaders on PBM, PPRV, and SBIR
December 8, 2025
Dear Congressional Leaders:On behalf of the Council of State Bioscience Associations (CSBA)—a national coalition of independent, state and territory-based organizations representing the full breadth of America’s biotechnology ecosystem—we write to…
BIO's Comments on Advisory Committee on Immunization Practices (ACIP) - December 2025
December 4, 2025
Re: Docket No. CDC-2025-0783; Advisory Committee on Immunization Practices (ACIP) MeetingDear Dr. Zadeh and Members of the ACIP:The Biotechnology Innovation Organization (BIO) appreciates the opportunity to provide comments to the Advisory Committee…
Testimony of BIO President & CEO John F. Crowley before the Senate Health, Education, Labor, and Pensions (HELP) Committee: “The Future of Biotech: Maintaining U.S. Competitiveness and Delivering Lifesaving Cures to Patients”
October 29, 2025
Chairman Cassidy, Ranking Member Sanders, and distinguished Members of the Committee:Thank you for the opportunity to appear before you today on behalf of the Biotechnology Innovation Organization (BIO), which represents more than 1,000…
BIO Statement on Vaccines and Autism
September 23, 2025
Phyllis Arthur, EVP, Health Policy and Programs, “Vaccines are one of the most important and effective innovations for the defense of public health. They have saved millions of lives and drastically reduced or eliminated deadly and debilitating…
BIO's Comments to CDC’s Advisory Committee on Immunization Practices (ACIP)
September 16, 2025
Re: Docket No. CDC-2025-0454; Advisory Committee on Immunization Practices (ACIP)The Biotechnology Innovation Organization (BIO) is appreciative of the opportunity to provide comments to the Advisory Committee on Immunization Practices (ACIP) in…